Your AI-Trained Oncology Knowledge Connection!

Radhika Appaya

Articles by Radhika Appaya

18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources

ByRadhika Appaya,Sarah Sammons, MD,Priyanka Sharma, MD,Yara Abdou,VK Gadi, MD, PhD,Taavy A. Miller,Spencer S. Langerman,Dominick Latremouille-Viau,Annie Guerin,Carmine Rossi,Emily McGovern,Gary Sopher,Vamsi Bollu,Natalia Bolotova,Şerban R. Iorga,Liz Santarsiero,Susan Dent, MD

June 30th 2025

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

ByRadhika Appaya,Erika P. Hamilton, MD,Thomas Decker,Hope S. Rugo, MD,Maria Fernandez Abad,Kevin Kalinsky, MD, MS,Qiang Liu,Mariya Rozenblit, MD,Barbara Radecka,Seock-Ah Im,Frances Visco,Alejandro Perez,Yogesh Chattar,Murat Akdere,Vaidyanathan Ganapathy,Sorcha Waters,Joyce O’Shaughnessy, MD

June 27th 2025

Latest Updated Articles

Trending on CancerNetwork

Proton Beam Therapy and IMRT Confer Similar AEs and QOL in Oropharyngeal Cancer

T-DXd Improves Invasive DFS vs T-DM1 in HER2+ Early Breast Cancer Subgroup

Adding 177Lu-PNT2002 to SBRT Improves PFS in Oligorecurrent Prostate Cancer

Certepetide/FOLFIRINOX Displays Encouraging Preliminary Feasibility in PDAC

PAM50 Biomarker May Predict Apalutamide Efficacy in Prostate Cancer

© 2025 MJH Life Sciences^®

All rights reserved.